{"database": "lobbying", "table": "lobbying_activities", "rows": [[2472366, "9d7a16b8-d63a-4300-8539-8167875bfded", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "NOVO NORDISK INC.", 2020, "second_quarter", "PHA", "H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B; H.R. 4244 MAGIC (Market Access for Generic Insulin Competition) Act to provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act)", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE", 60000, null, 0, 0, "2020-07-17T13:58:59.297000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2472366"], "units": {}, "query_ms": 0.35600701812654734, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}